2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery.
Alexander Wahba, Milan Milojevic, Christa Boer...
https://pubmed.ncbi.nlm.nih.gov/31576396/Actively Recruiting
Led by Aristotle University Of Thessaloniki · Updated on 2026-03-30
1300
Participants Needed
13
Research Sites
12 weeks
Total Duration
Researchers are evaluating the effectiveness of minimally invasive extracorporeal circulation MiECC compared to conventional cardiopulmonary bypass cCPB in reducing serious complications after cardiac surgery. This large multicenter randomized controlled trial, led by the Aristotle University of Thessaloniki, focuses on patients undergoing coronary artery bypass grafting, aortic valve replacement, or both, aiming to see if MiECC can lower the rate of serious postoperative problems such as death, heart attack, stroke, kidney injury, and respiratory complications within 30 days after surgery. Participants are assigned to receive cardiac surgery using either a MiECC system or a conventional heart-lung machine cCPB. The study includes patients undergoing elective or urgent surgery without circulatory arrest and excludes those needing emergency operations or major aortic surgery. The trial will recruit about 1,300 participants across 10 to 15 centers worldwide to detect meaningful differences in postoperative outcomes. During the study, participants will be monitored for serious adverse events up to 30 days after surgery. Researchers will also track blood transfusions, time spent in the cardiac intensive care unit and hospital, new onset postoperative atrial fibrillation, delirium, and health-related quality of life up to 90 days after surgery. Safety and recovery will be carefully assessed through hospital records and clinical evaluations throughout the initial hospital stay and follow-up periods.
CONDITIONS
MiECC Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery (MiECS)
G
Georgios Papazisis, Assoc. Prof.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Aristotle University Of Thessaloniki
Lead Sponsor
Minimal Invasive Extracorporeal Technologies International Society (MiECTiS)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 week
Participants undergo cardiac surgery using either Minimal Invasive Extracorporeal Circulation (MiECC) or conventional cardiopulmonary bypass (cCPB), followed by immediate recovery and monitoring in the cardiac intensive care unit.
Hospital stay including surgery and cardiac ICU monitoring
Duration - Up to 90 days after surgery
Participants are monitored for serious postoperative complications, recovery progress, and health-related quality of life after discharge from the hospital.
Approximately 2 follow-up visits within 90 days
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Alexander Wahba, Milan Milojevic, Christa Boer...
https://pubmed.ncbi.nlm.nih.gov/31576396/Marco Ranucci, Ian Johnson, Timothy Willcox...
https://pubmed.ncbi.nlm.nih.gov/29778331/Mariusz Kowalewski, Wojciech Pawliszak, Giuseppe Maria Raffa...
https://pubmed.ncbi.nlm.nih.gov/26537755/Kyriakos Anastasiadis, Polychronis Antonitsis, Christos Asteriou...
https://pubmed.ncbi.nlm.nih.gov/34137323/Kyriakos Anastasiadis, John Murkin, Polychronis Antonitsis...
https://pubmed.ncbi.nlm.nih.gov/26819269/Kyriakos Anastasiadis, Polychronis Antonitsis, Georgios Papazisis...
https://pubmed.ncbi.nlm.nih.gov/39089011/Kyriakos Anastasiadis, Helena Argiriadou, Apostolos Deliopoulos...
https://pubmed.ncbi.nlm.nih.gov/31293801/COMICS investigators, The COMICS investigators
https://pubmed.ncbi.nlm.nih.gov/32781894/Aristotle University Of Thessaloniki
Lead Sponsor
Minimal Invasive Extracorporeal Technologies International Society (MiECTiS)
Collaborating Sponsor